New PET tracer aims to spot prostate cancer more clearly
NCT ID NCT03995888
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a new radioactive imaging agent called rhPSMA-7.3 (18F) in 24 people: some healthy volunteers and some with prostate cancer. The goal was to check safety and see how the agent spreads in the body and how well it lights up cancer on PET scans. The study is complete, but results are not yet reported.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- rhPSMA-7.3 (18F) injection
- What this could lead to
- If successful, this could lead to a more accurate PET scan to detect prostate cancer, helping doctors see where the cancer is in the body.
- What could go wrong
- This is an early phase 1 study with only 24 people, so it is too small to prove the scan works better than current methods. The main goal is safety, not yet effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinical Research Services Turku - CRST Oy
Turku, FI-20520, Finland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?